Market capitalization | JPY2.85t |
Enterprise Value | JPY3.52t |
PER (TTM) P/E ratio | 221.29 |
EV/FCF (TTM) EV/FCF | 24.58 |
EV/Sales (TTM) EV/Sales | 2.20 |
P/S ratio (TTM) P/S ratio | 1.78 |
P/B ratio (TTM) P/B ratio | 1.79 |
Dividend yield | 4.65% |
Last dividend (FY25) | JPY74.00 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
14 Analysts have issued a Astellas Pharma forecast:
14 Analysts have issued a Astellas Pharma forecast:
Mar '24 |
+/-
%
|
||
Turnover | 1,603,671 1,603,671 |
6%
6%
|
|
Gross income | 1,212,367 1,212,367 |
2%
2%
|
|
EBITDA | 335,910 335,910 |
14%
14%
|
EBIT (operating result) EBIT | 178,070 178,070 |
38%
38%
|
Net profit | 12,905 12,905 |
87%
87%
|
Figures in millions JPY.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Naoki Okamura |
Employees | 14,754 |
Founded | 1923 |
Website | www.astellas.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.